- 现金
- 222032 元
- 精华
- 285
- 帖子
- 67620
- 注册时间
- 2001-11-10
- 最后登录
- 2023-5-7
|
1楼
发表于 2004-9-12 04:54
Journal of Viral Hepatitis
Volume 11 Issue 5 Page 443 - September 2004
doi:10.1111/j.1365-2893.2004.00523.x
[B]Kinetics of hepatitis B viral load during 48 weeks of treatment with 600 mg
vs 100 mg of lamivudine daily*[/B]
C. C. Wang1, S. Holte2, M.-L. Huang2, S. L. Sacks3, R. Engelberg4, J.
Ferrenberg2, M. Shuhart1 and L. Corey1,2,4
Summary. Oral therapy for chronic hepatitis B remains suboptimal.
Mathematical modelling of viral decay kinetics to rapidly assess potential
antiviral regimens has proved valuable for human immunodeficiency virus and
cytomegalovirus. We defined the kinetics of viral replication in 10 chronic
hepatitis B patients randomized to lamivudine 100 mg vs 600 mg for 48 weeks.
Viral decay kinetics conformed to a biphasic pattern in nine of 10 subjects.
Persons receiving 600 mg daily of lamivudine exhibited a 1.6-fold faster
decay rate in the infected cell compartment (0.028/day vs 0.017/day, P =
0.06) and a greater overall change in serum viral load when compared with
those receiving 100 mg (4.06 vs 1.52 log10 copies/mL, P = 0.08). More potent
therapy appeared to result in more rapid decrease in the infected cell
population. Studies using mathematical modelling of viral decay may be a
useful method to evaluate single or combination therapy for HBV infection in
vivo.
|
|